sb 203580 has been researched along with regorafenib in 3 studies
Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (regorafenib) | Trials (regorafenib) | Recent Studies (post-2010) (regorafenib) |
---|---|---|---|---|---|
3,489 | 4 | 1,137 | 884 | 122 | 857 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (66.67) | 24.3611 |
2020's | 1 (33.33) | 2.80 |
Authors | Studies |
---|---|
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
Bharate, SB; Raghuvanshi, R | 1 |
Chiang, CH; Chung, JG; Hsu, FT | 1 |
3 other study(ies) available for sb 203580 and regorafenib
Article | Year |
---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Approval; Drug Repositioning; High-Throughput Screening Assays; Humans; Protein Kinase Inhibitors; SARS-CoV-2; United States; United States Food and Drug Administration; Virus Diseases | 2022 |
Regorefenib induces extrinsic/intrinsic apoptosis and inhibits MAPK/NF-κB-modulated tumor progression in bladder cancer in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Disease Progression; Humans; Imidazoles; MAP Kinase Signaling System; Mice; Mitogen-Activated Protein Kinases; Neoplasm Transplantation; NF-kappa B; p38 Mitogen-Activated Protein Kinases; Phenylurea Compounds; Pyridines; Signal Transduction; Urinary Bladder Neoplasms | 2019 |